Guías para el manejo de las enfermedades más frecuentes del pelo
Palabras clave:
alopecia, areata, androgenética (sic.)Resumen
Las enfermedades del pelo se hacen cada día más frecuentes en la consulta y el dermatólogo se ve enfrentado a su manejo. Esta guía pretende dar una serie de indicaciones para el enfoque clínico del paciente, y el manejo terapéutico, con base en los estudios clínicos y la experiencia de los autores. Se hace énfasis en las entidades más vistas en la consulta, como la alopecia areata, la alopecia en efluvio telógeno, las alopecias androgénicas femeninas y masculinas y las alopecias cicatriciales.
Biografía del autor/a
Sol Beatriz Jiménez
Médica dermatóloga; Jefe del servicio de Dermatología, docente de Dermatología, Universidad CES, Medellín, Colombia
Claudia Uribe
Médica dermatóloga, especialización en pelo, Universidad de París; docente de Dermatología, Universidad CES, Medellín, Colombia
Isabel Restrepo
Médica dermatóloga, especialista en pelo, Universidad de Canadá; docente de Dermatología, Universidad CES, Medellín, Colombia
Referencias bibliográficas
1. Alkhalifah A, Alsantali A, Wang E, MacElwee K, Shapiro J. Alopecia areata update. Part I. Clinical picture, histopathology and patogénesis. J Am Acad Dermatol. 2010;62:177-88.
2. Galán M, Rodríguez A, Moreno J.C. Actualización terapéutica en alopecia areata. Actas Dermatosifilograf. 2009;100:266-76.
3. Alkhalifah A, Alsantali A, Wang E, MacElwee K, Shapiro J. Alopecia areata update. Part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
4. Garg S, Messenger A. Alopecia areata: Evidence-based treatments. Cutaneus Medicine and Surgery. 2009;28:15-8.
5. Kos L, Conlon J. An update on alopecia areata. Curr Opin Pediatr. 2009;21:475-80.
6. Mounsey A, Reed S. Diagnosing and treating hair loss. Am Fam Physician. 2009;80:356-62.
7. Katolious A, Alevizou A, Bozi E, Georgala S, Mistidou M, Kageromitros D. Biologic agents and alopecia areata. Dermatology. 2009;218:184-5.
8. Joon B, Uk Min S, Park K, Unger W, Robin U, Wesley C. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatol Treat. 2008;18:216-20.
9. Lew B, Shin M, Sim W. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol. 2009;60:85-93.
10. Strober B, Menon K, McMichael A, Hordinsky M, et al. Alefacept for severe alopecia mareata. Arch Dermatol. 2009;145:1262-6.
11. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1 % gel for alopecia areata. J Am Acad Dermatol. 2009;61:592-9.
12. Ochoa B, Sab D, Wang G, Stamper R, Price V. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61: 530-2.
13. Halilovic K, Prohic A. Nail changes in alopecia areata: Frecuency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23:240-1.
14. Ehsani AH, Toosi S, Seirafi H, Akhyani M, Hosseini M, Azadi R, et al. Capsaicin Vs. clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol. 2009;23:1452-3.
15. Kaufman G, Dovidio R, Kaldawy A, Assy B, Ullmann Y. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic? Exp Dermatol. 2010;19:347-9
16. Ghanizadeh A. Comorbidity of psyquiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. International J Dermatol. 2008;47:1118-20.
17. van den Biggelaar, Smolders J, Jansen J. Complementary and alternative medicine in alopecia areata. Am J Clin Dermatol. 2010;11:11-20.
18. Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermatoscopy in alopecia areata: Analysis de 300 cases. Int J Dermatol. 2008;47:688-93.
19. Tosti A, Whiting D, Iorizzo M, Pazzaglia M, Misciali C,Vincenzi C, et al. The role of scalp dermatoscopy in the diagnosis in alopecia areata incognita. J Am Acad Dermatol. 2008;59:64-7.
20. Wallace M, Berker A. Hair diagnosis and signs: Use of dermatoscopy. Clin Exp Dermatol. 2009;35:41-6.
21. Tosti A, Duque B. Dermatoscopy in hair desorders. J Egypt Women Dermatol. 2010;7:1-4.
22. Mounsey A, Reed S. Diagnosing and treating hair loss. Am Fam Physician. 2009;80:356-62.
23. Maryam K, Hassan S, Farshad F, Parastoo B, Vahide L. The efficacy of topical diphencyprone in the treatment of alopecia areata. Indian J Dermatol Venereol Leprol. 2009;54:88-9.
24. Mohan KH, Balachandran C, Shenoi SD, Rao R, Sripathi H, Prabhu S. Topical dinitroclorobenzene (DNCB) for alopecia areata: Revised. Indian J Dermatol Venereol Leprol. 2008;74:401-2.
25. Fernández G, Harto A, García I, Pérez B, Arrazola J, Jaen P. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol. 2008;33:585-7.
26. Koc E, Tunca M, Akar A, Kurumlu Z. Int J Dermatol. 2008;47:1088-9.
27. Evans S, Altaykan A, Sahin S, Kolemen F. Phototherapy in childhood. Pediatr Dermatol. 2008;25:599-605.
28. Stefanato C. Histopathology of alopecia: A clinicopathological approach to diagnosis. Histopathology. 2010;56:24-38.
29. Barahmani N, Schabath M, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61:581-91.
30. Tucker P. Bald is a beautiful? The psychosocial impact of alopecia areata. J Health Psychol. 2009;14:142-50.
31. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2008;74:611-3.
32. Rashidi T, Alamdari A. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-2.
33. Trüeb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges. 2010;8:284-98.
34. Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol. 1961;83:175-98.
35. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27:389-5.
36. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129:356-63.
37. Hoffmann R. TrichoScan: Combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol. 2001;11:362-8.
38. Trueb RM. Idiopathic chronic telogen effluvium in the woman. Hautarzt. 2000;51(12):899-905
39. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54:824-44.
40. T. Shrivastava SB. Diffuse hair loss in an adult female:aproch to diagnosis and management. Indian J Dermatol Venerol Leprol 2009;75:20-7
41. Shapiro J. Safety of topical minoxidil solution: A one-year, prospective, observational study. J Cutan Med Surg. 2003;7:322-9.
42. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J. Am Acad Dermatol. 2008;59:547-66.
43. Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes. 2009;16:246-53.
44. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11:1295-304.
45. Leavitt M, Charles G, Heyman EM. Chairman LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29:283-92.
46. Avram MR, Rogers NE. The use of low-level light for hair growth: Part I. J Cosmet Laser Ther. 2009;11:110-7.
47. Kaufman KD, Girman CJ, Round EM, Johnson-Levonas AO, Shah AK, Rotonda J. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): Long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol. 2008;18:407-11.
48. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18:400-6.
49. García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: Better response in patients under 26 years old. Br J Dermatol. 2008;158:1121-4.
50. Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol. 2007;12:591-601.
51. Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BMJ. 2010;105:456-9.
52. Laborde E, Brannigan RE. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010;31:e1-2.
53. Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: A TEM and FISH study. Arch Androl. 2007;53:229-33.
54. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5 alpha-reductase inhibitors for the enlarged prostate. M.Clin Ther. 2007;29:17-25.
55. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML. et al. The importance of dual 5 alpha-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014-23.
56. Rogers E, Marc R, Avram R. Medical treatment for male and female pattern hair loss. J Am Acad Dermatol. 2008;59:547-66.
57. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6:9-13.
58. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss.. J Am Acad Dermatol. 2010;63:252-8.
59. Francisco M, Camacho-Martínez A. Hair loss in women. Semin Cutan Med Surg. 2009;28:19-32.
60. Chen W, Yang CC, Todorova A, Al Khuzaei S, Chiu HC, Worret WI, et al. Hair loss in elderly women. Eur J Dermatol. 2010;20:145-51.
61. Rivera R, Guerra-Tapia A. Manejo de la alopecia androgenética en mujeres posmenopáusicas. Actas Dermosifiliogr. 2008;99:257-61
62. Lucky AW, Piacquadio DJ, . Ditre CM, Dunlap F, Kantor I, Pandya AG. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541-53.
63. Dinh QQ, Sinclair R. Female pattern hair loss: Current treatment concepts. Clin Interv Aging. 2007;2:189-99.
64. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J. 2008;14:1.
65. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol. 2007;48:43-5.
66. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28:611-8.
67. Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010;44:1090-7.
68. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995;38:1260-70.
69. George PM, Tunnessen WW Jr. Childhood discoid lupus erythematosus. Arch Dermatol. 1993;129:613-7.
70. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
71. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. Second edition. New York; McGraw-Hil:2003p. 363-98.
72. Heffernan MP, Nelson MM, Smith DI, Chung JH. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol. 2005;141:1170-1.
73. Jones SK. Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol. 1999;140:3-7.
74. Wenzel J, Bieber T, Uerlich M, Tüting T. Systemic treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2003;1:694-704.
75. Rubenstein DJ, Huntley AC. Keratotic lupus erythematosus: Treatment with isotretinoin. J Am Acad Dermatol. 1986;14:910-4.
76. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: Dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-73.
77. Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus. 1999;8:240-3.
78. Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006;54:892-5.
79. Gül U, Gönül M, Cakmak SK, Kiliç A, Demiriz M. A case of generalized discoid lupus erythematosus: Successful treatment with imiquimod cream 5%. Adv Ther. 2006;23:787-92.
80. Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, BerthJones J, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161:1365-70.
81. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol. 1994;130:1407.
82. Serrano S, Martín A, Sánchez J. Piccardi-Graham Little-Lasseur sindrome. Actas Dermosifiliogr. 1981;72:257-60.
83. Mehregan DA, van Hale HM, Muller SA. Lichen plano pilaris: Clinical and pathologic study of forty-five patients. J Am Acad Dermatol. 1992;27:935-42.
84. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
85. Newton RC, Hebert AA, Freese TW, Solomon AR. Scarring alopecia. Dermatol Clin. 1987;5:603-18.
86. Wiseman MC, Shapiro J. Scarring alopecia. J Cutan Med Surg. 1999;3(Suppl.3):S45-8.
87. van Beek MJ, Piette WW. Antimalarials. Dermatol Clin. 2001;19:147-60.
88. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
89. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA. 1982;79:175-8.
90. Shapiro J. Cicatricial alopecias. Dermatol Ther. 2008;21:211.
91. Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006;25:56-9.
92. Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen plano pilaris. J Am Acad Dermatol. 2003;49:667-71.
93. Heymann WR. Mycophenolate mofetil. J Am Acad Dermatol. 2005;53:1045-6.
94. Tursen U, Api H, Kaya T, Ikizoglu G. Treatment of lichen plano pilaris with mycophenolate mofetil. Dermatol Online J. 2004;10:24.
95. Handler HL. Isotretinoin for oral lichen planus. J Am Acad Dermatol. 1984;10:674.
96. Sullivan JR, Kossard S. Acquired scalp alopecia. Part I: A review. Australas J Dermatol. 1998;39:207-19.
97. Helfman RJ, Brickman M, Fahey J. Isotretinoin dermatitis simulating acute pityriasis rosea. Cutis. 1984;33:297-300.
98. Berger RS, Hayes TJ, Dixon SL. Erythema dyschromicum perstans and lichen planus: Are they related? J Am Acad Dermatol. 1989;21:438-42.
99. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol. 1995;104:523-5.
100. Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen plano pilaris: The Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol. 2007;57:47-53.
101. Brocq L, Lenglet E, Ayrignac J. Recherchers sur alopecie atrophiante variante seudo-pelade. Ann Dermato Syphil. 1905;6:1-32.
102. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg. 2006;25:41-50.
103. Sellheyer K, Bergfeld WF. Histopathologic evaluation of alopecias. Am J Dermatopathol. 2006;28:236-59.
104. Sullivan JR, Kossard S. Acquired scalp alopecia. Part I: A review. Australas J Dermatol. 1998;39:207-19.
105. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
106. Sperling LC, Solomon AR, Whiting DA. A new look at scarring alopecia. Arch Dermatol. 2000;136:235-42.
107. Sahl WJ. Pseudopelade: An inherited alopecia. Int J Dermatol. 1996;35:715-9.
108. Collier PM, James MP. Pseudopelade of Brocq occurring in two brothers in childhood. Clin Exp Dermatol. 1994;19:61-4.
109. Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: Clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50:25-32.
110. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
111. Shapiro J. Cicatricial (scarring) alopecias. Shapiro J, editor. Hair loss: principles of diagnosis and management of alopecia. London: Martin Dunitz; 2002.p. 155-74.
112. Wiseman MC, Shapiro J. Scarring alopecia. J Cutan Med Surg. 1999;3(Suppl.3):S45-8.
113. Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006;25:56-9.
114. Gruenfeld RL. Uber folliculitis decalvans. J Arch Dermatol Res. 1909;95:331-66.
115. Sperling LC, Skelton HG 3rd, Smith KJ, Sau P, Friedman K. Follicular degeneration syndrome in men. Arch Dermatol. 1994;130:763-9.
116. Olsen EA, Callender V, Sperling L, McMichael A, Anstrom KJ, Bergfeld W, et al. Central scalp alopecia photographic scale in African American women. Dermatol Ther. 2008;21:264-7.
117. LoPresti P, Papa CM, Kligman AM. Hot comb alopecia. Arch Dermatol. 1968;98:234-8.
118. Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther. 2004;17:164-76.
119. Khumalo NP. Grooming and central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2010;62:507-8.
120. Templeton SF, Solomon AR. Scarring alopecia: A classification based on microscopic criteria. J Cutan Pathol. 1994;21:97-109.
121. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
122. Sperling LC, Solomon AR, Whiting DA. A new look at scarring alopecia. Arch Dermatol. 2000;136:235-42.
123. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. 2nd edition. New York: McGraw-Hill; 2003 p. 363-98.
124. Newton RC, Hebert AA, Freese TW, Solomon AR. Scarring alopecia. Dermatol Clin. 1987;5:603-18.
125. Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Perifolliculitis capitis abscedens et suffodiens successfully controlled with topical isotretinoin. Eur J Dermatol. 2003;13:192-5.
126. Ljubojevic S, Pasic A, Lipozencic J, Skerlev M. Perifolliculitis capitis abscedens et suffodiens. J Eur Acad Dermatol Venereol. 2005;19:719-21.
127. Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis abscedens et suffodiens with combined isotretinoin and dapsone. J Dtsch Dermatol Ges. 2008;6:44-7.
128. Berne B, Venge P, Ohman S. Perifolliculitis capitis abscedens et suffodiens (Hoffman). Complete healing associated with oral zinc therapy. Arch Dermatol. 1985;121:1028-30.
129. Georgala S, Korfitis C, Ioannidou D, Alestas T, Kylafis G, Georgala C. Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: Case reports. Cutis. 2008;82:195-8.
130. Wu WY, Otberg N, McElwee KJ, Shapiro J. Diagnosis and management of primary cicatricial alopecia: Part II. Skinmed. 2008;7:78-83.
131. Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: Control of inflammation within residual structural disease. Arch Dermatol. 2010;146:517-20.
132. Krasner BD, Hamzavi FH, Murakawa GJ, Hamzavi IH. Dissecting cellulitis treated with the long-pulsed Nd: YAG laser. Dermatol Surg. 2006;32:1039-44.
133. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
134. Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: Clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50:25-32.
135. Chandrawansa PH, Giam YC. Folliculitis decalvans –a retrospective study in a tertiary referred centre, over five years. Singapore Med J. 2003;44:84-7.
136. Powell JJ, Dawber RP, Gatter K. Folliculitis decalvans including tufted folliculitis: Clinical, histological and therapeutic findings. Br J Dermatol. 1999;140:328-33.
137. Powell J, Dawber RP. Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors. Br J Dermatol. 2001;144:428-9.
138. Annessi G. Tufted folliculitis of the scalp: A distinctive clinicohistological variant of folliculitis decalvans. Br J Dermatol. 1998;138:799-805.
139. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
140. Sullivan JR, Kossard S. Acquired scalp alopecia. Part II: A review. Australas J Dermatol. 1999;40:61-70.
141. Abeck D, Korting HC, Braun-Falco O. Folliculitis decalvans. Longlasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol. 1992;72:143-5.
142. Kaur S, Kanwar AJ. Folliculitis decalvans: Successful treatmentwith a combination of rifampicin and topical mupirocin. J Dermatol. 2002;29:180-1.
143. Powell J, Dawber RP. Folliculitis decalvans and tufted folliculitis are specific infective diseases that may lead to scarring, but are not a subset of central centrifugal scarring alopecia. Arch Dermatol. 2001;137:373-4.
144. Brozena SJ, Cohen LE, Fenske NA. Folliculitis decalvans –response to rifampicin. Cutis. 1988;42:512-5.
145. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. Second edition. New York; McGraw-Hill, New York: 2003 P.
146. Gemmeke A, Wollina U. Folliculitis decalvans of the scalp: Response to triple therapy with isotretinoin, clindamycin, and prednisolone. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:184-6.
147. Paquet P, Piérard GE. Dapsone treatment of folliculitis decalvans. Ann Dermatol Venereol. 2004;131:195-7.
148. Salinger D. Treatment of folliculitis decalvans with tyrosine. Exp Dermatol. 1999;8:363-4.
149. Walker SL, Smith HR, Lun K, Griffiths WA. Improvement of folliculitis decalvans following shaving of the scalp. Br J Dermatol. 2000;142:1245-6.
150. Parlette EC, Kroeger N, Ross EV. Nd: YAG laser treatment of recalcitrant folliculitis decalvans. Dermatol Surg. 2004;30:1152-4.
2. Galán M, Rodríguez A, Moreno J.C. Actualización terapéutica en alopecia areata. Actas Dermatosifilograf. 2009;100:266-76.
3. Alkhalifah A, Alsantali A, Wang E, MacElwee K, Shapiro J. Alopecia areata update. Part II. Treatment. J Am Acad Dermatol. 2010;62:191-202.
4. Garg S, Messenger A. Alopecia areata: Evidence-based treatments. Cutaneus Medicine and Surgery. 2009;28:15-8.
5. Kos L, Conlon J. An update on alopecia areata. Curr Opin Pediatr. 2009;21:475-80.
6. Mounsey A, Reed S. Diagnosing and treating hair loss. Am Fam Physician. 2009;80:356-62.
7. Katolious A, Alevizou A, Bozi E, Georgala S, Mistidou M, Kageromitros D. Biologic agents and alopecia areata. Dermatology. 2009;218:184-5.
8. Joon B, Uk Min S, Park K, Unger W, Robin U, Wesley C. Combination therapy of cyclosporine and methylprednisolone on severe alopecia areata. J Dermatol Treat. 2008;18:216-20.
9. Lew B, Shin M, Sim W. Acute diffuse and total alopecia: A new subtype of alopecia areata with a favorable prognosis. J Am Acad Dermatol. 2009;60:85-93.
10. Strober B, Menon K, McMichael A, Hordinsky M, et al. Alefacept for severe alopecia mareata. Arch Dermatol. 2009;145:1262-6.
11. Talpur R, Vu J, Bassett R, Stevens V, Duvic M. Phase I/II randomized bilateral half-head comparison of topical bexarotene 1 % gel for alopecia areata. J Am Acad Dermatol. 2009;61:592-9.
12. Ochoa B, Sab D, Wang G, Stamper R, Price V. Instilled bimatoprost ophthalmic solution in patients with eyelash alopecia areata. J Am Acad Dermatol. 2009;61: 530-2.
13. Halilovic K, Prohic A. Nail changes in alopecia areata: Frecuency and clinical presentation. J Eur Acad Dermatol Venereol. 2009;23:240-1.
14. Ehsani AH, Toosi S, Seirafi H, Akhyani M, Hosseini M, Azadi R, et al. Capsaicin Vs. clobetasol for the treatment of localized alopecia areata. J Eur Acad Dermatol Venereol. 2009;23:1452-3.
15. Kaufman G, Dovidio R, Kaldawy A, Assy B, Ullmann Y. An unexpected twist in alopecia areata pathogenesis: are NK cells protective and CD49b+ T cells pathogenic? Exp Dermatol. 2010;19:347-9
16. Ghanizadeh A. Comorbidity of psyquiatric disorders in children and adolescents with alopecia areata in a child and adolescent psychiatry clinical sample. International J Dermatol. 2008;47:1118-20.
17. van den Biggelaar, Smolders J, Jansen J. Complementary and alternative medicine in alopecia areata. Am J Clin Dermatol. 2010;11:11-20.
18. Inui S, Nakajima T, Nakagawa K, Itami S. Clinical significance of dermatoscopy in alopecia areata: Analysis de 300 cases. Int J Dermatol. 2008;47:688-93.
19. Tosti A, Whiting D, Iorizzo M, Pazzaglia M, Misciali C,Vincenzi C, et al. The role of scalp dermatoscopy in the diagnosis in alopecia areata incognita. J Am Acad Dermatol. 2008;59:64-7.
20. Wallace M, Berker A. Hair diagnosis and signs: Use of dermatoscopy. Clin Exp Dermatol. 2009;35:41-6.
21. Tosti A, Duque B. Dermatoscopy in hair desorders. J Egypt Women Dermatol. 2010;7:1-4.
22. Mounsey A, Reed S. Diagnosing and treating hair loss. Am Fam Physician. 2009;80:356-62.
23. Maryam K, Hassan S, Farshad F, Parastoo B, Vahide L. The efficacy of topical diphencyprone in the treatment of alopecia areata. Indian J Dermatol Venereol Leprol. 2009;54:88-9.
24. Mohan KH, Balachandran C, Shenoi SD, Rao R, Sripathi H, Prabhu S. Topical dinitroclorobenzene (DNCB) for alopecia areata: Revised. Indian J Dermatol Venereol Leprol. 2008;74:401-2.
25. Fernández G, Harto A, García I, Pérez B, Arrazola J, Jaen P. Failure to treat alopecia areata with photodynamic therapy. Clin Exp Dermatol. 2008;33:585-7.
26. Koc E, Tunca M, Akar A, Kurumlu Z. Int J Dermatol. 2008;47:1088-9.
27. Evans S, Altaykan A, Sahin S, Kolemen F. Phototherapy in childhood. Pediatr Dermatol. 2008;25:599-605.
28. Stefanato C. Histopathology of alopecia: A clinicopathological approach to diagnosis. Histopathology. 2010;56:24-38.
29. Barahmani N, Schabath M, Duvic M. History of atopy or autoimmunity increases risk of alopecia areata. J Am Acad Dermatol. 2009;61:581-91.
30. Tucker P. Bald is a beautiful? The psychosocial impact of alopecia areata. J Health Psychol. 2009;14:142-50.
31. Aghaei S. An uncontrolled, open label study of sulfasalazine in severe alopecia areata. Indian J Dermatol Venereol Leprol. 2008;74:611-3.
32. Rashidi T, Alamdari A. Treatment of persistent alopecia areata with sulfasalazine. Int J Dermatol. 2008;47:850-2.
33. Trüeb RM. Systematic approach to hair loss in women. J Dtsch Dermatol Ges. 2010;8:284-98.
34. Kligman AM. Pathologic dynamics of human hair loss. I. Telogen effluvium. Arch Dermatol. 1961;83:175-98.
35. Harrison S, Sinclair R. Telogen effluvium. Clin Exp Dermatol. 2002;27:389-5.
36. Headington JT. Telogen effluvium. New concepts and review. Arch Dermatol. 1993;129:356-63.
37. Hoffmann R. TrichoScan: Combining epiluminescence microscopy with digital image analysis for the measurement of hair growth in vivo. Eur J Dermatol. 2001;11:362-8.
38. Trueb RM. Idiopathic chronic telogen effluvium in the woman. Hautarzt. 2000;51(12):899-905
39. Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54:824-44.
40. T. Shrivastava SB. Diffuse hair loss in an adult female:aproch to diagnosis and management. Indian J Dermatol Venerol Leprol 2009;75:20-7
41. Shapiro J. Safety of topical minoxidil solution: A one-year, prospective, observational study. J Cutan Med Surg. 2003;7:322-9.
42. Rogers NE, Avram MR. Medical treatments for male and female pattern hair loss. J. Am Acad Dermatol. 2008;59:547-66.
43. Alsantali A, Shapiro J. Androgens and hair loss. Curr Opin Endocrinol Diabetes Obes. 2009;16:246-53.
44. Rathnayake D, Sinclair R. Male androgenetic alopecia. Expert Opin Pharmacother. 2010;11:1295-304.
45. Leavitt M, Charles G, Heyman EM. Chairman LaserComb laser phototherapy device in the treatment of male androgenetic alopecia: A randomized, double-blind, sham device-controlled, multicentre trial. Clin Drug Investig. 2009;29:283-92.
46. Avram MR, Rogers NE. The use of low-level light for hair growth: Part I. J Cosmet Laser Ther. 2009;11:110-7.
47. Kaufman KD, Girman CJ, Round EM, Johnson-Levonas AO, Shah AK, Rotonda J. Progression of hair loss in men with androgenetic alopecia (male pattern hair loss): Long-term (5-year) controlled observational data in placebo-treated patients. Eur J Dermatol. 2008;18:407-11.
48. Kaufman KD, Rotonda J, Shah AK, Meehan AG. Long-term treatment with finasteride 1 mg decreases the likelihood of developing further visible hair loss in men with androgenetic alopecia (male pattern hair loss). Eur J Dermatol. 2008;18:400-6.
49. García-Hernández MJ, Fernández-Crehuet JL. Value of hormonal levels in patients with male androgenetic alopecia treated with finasteride: Better response in patients under 26 years old. Br J Dermatol. 2008;158:1121-4.
50. Kumar R, Singh B, Bakshi G, Katare OP. Development of liposomal systems of finasteride for topical applications: Design, characterization, and in vitro evaluation. Pharm Dev Technol. 2007;12:591-601.
51. Lebdai S, Bigot P, Azzouzi AR. High-grade prostate cancer and finasteride. BMJ. 2010;105:456-9.
52. Laborde E, Brannigan RE. Effect of 1-mg dose of finasteride on spermatogenesis and pregnancy. J Androl. 2010;31:e1-2.
53. Collodel G, Scapigliati G, Moretti E. Spermatozoa and chronic treatment with finasteride: A TEM and FISH study. Arch Androl. 2007;53:229-33.
54. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5 alpha-reductase inhibitors for the enlarged prostate. M.Clin Ther. 2007;29:17-25.
55. Olsen EA, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML. et al. The importance of dual 5 alpha-reductase inhibition in the treatment of male pattern hair loss: Results of a randomized placebo-controlled study of dutasteride versus finasteride. J Am Acad Dermatol. 2006;55:1014-23.
56. Rogers E, Marc R, Avram R. Medical treatment for male and female pattern hair loss. J Am Acad Dermatol. 2008;59:547-66.
57. Stough D. Dutasteride improves male pattern hair loss in a randomized study in identical twins. J Cosmet Dermatol. 2007;6:9-13.
58. Eun HC, Kwon OS, Yeon JH, Shin HS, Kim BY, Ro BI, et al. Efficacy, safety and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss.. J Am Acad Dermatol. 2010;63:252-8.
59. Francisco M, Camacho-Martínez A. Hair loss in women. Semin Cutan Med Surg. 2009;28:19-32.
60. Chen W, Yang CC, Todorova A, Al Khuzaei S, Chiu HC, Worret WI, et al. Hair loss in elderly women. Eur J Dermatol. 2010;20:145-51.
61. Rivera R, Guerra-Tapia A. Manejo de la alopecia androgenética en mujeres posmenopáusicas. Actas Dermosifiliogr. 2008;99:257-61
62. Lucky AW, Piacquadio DJ, . Ditre CM, Dunlap F, Kantor I, Pandya AG. A randomized, placebo-controlled trial of 5% and 2% topical minoxidil solutions in the treatment of female pattern hair loss. J Am Acad Dermatol. 2004;50:541-53.
63. Dinh QQ, Sinclair R. Female pattern hair loss: Current treatment concepts. Clin Interv Aging. 2007;2:189-99.
64. Scheinfeld N. A review of hormonal therapy for female pattern (androgenic) alopecia. Dermatol Online J. 2008;14:1.
65. Hoedemaker C, van Egmond S, Sinclair R. Treatment of female pattern hair loss with a combination of spironolactone and minoxidil. Australas J Dermatol. 2007;48:43-5.
66. Rathnayake D, Sinclair R. Innovative use of spironolactone as an antiandrogen in the treatment of female pattern hair loss. Dermatol Clin. 2010;28:611-8.
67. Stout SM, Stumpf JL. Finasteride treatment of hair loss in women. Ann Pharmacother. 2010;44:1090-7.
68. McCarty DJ, Manzi S, Medsger TA Jr, Ramsey-Goldman R, LaPorte RE, Kwoh CK. Incidence of systemic lupus erythematosus. Race and gender differences. Arthritis Rheum. 1995;38:1260-70.
69. George PM, Tunnessen WW Jr. Childhood discoid lupus erythematosus. Arch Dermatol. 1993;129:613-7.
70. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
71. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. Second edition. New York; McGraw-Hil:2003p. 363-98.
72. Heffernan MP, Nelson MM, Smith DI, Chung JH. 0.1% tacrolimus ointment in the treatment of discoid lupus erythematosus. Arch Dermatol. 2005;141:1170-1.
73. Jones SK. Ocular toxicity and hydroxychloroquine: Guidelines for screening. Br J Dermatol. 1999;140:3-7.
74. Wenzel J, Bieber T, Uerlich M, Tüting T. Systemic treatment of cutaneous lupus erythematosus. J Dtsch Dermatol Ges. 2003;1:694-704.
75. Rubenstein DJ, Huntley AC. Keratotic lupus erythematosus: Treatment with isotretinoin. J Am Acad Dermatol. 1986;14:910-4.
76. Wu JJ, Huang DB, Pang KR, Hsu S, Tyring SK. Thalidomide: Dermatological indications, mechanisms of action and side-effects. Br J Dermatol. 2005;153:254-73.
77. Neri R, Mosca M, Bernacchi E, Bombardieri S. A case of SLE with acute, subacute and chronic cutaneous lesions successfully treated with dapsone. Lupus. 1999;8:240-3.
78. Clayton TH, Ogden S, Goodfield MD. Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab. J Am Acad Dermatol. 2006;54:892-5.
79. Gül U, Gönül M, Cakmak SK, Kiliç A, Demiriz M. A case of generalized discoid lupus erythematosus: Successful treatment with imiquimod cream 5%. Adv Ther. 2006;23:787-92.
80. Jemec GB, Ullman S, Goodfield M, Bygum A, Olesen AB, BerthJones J, et al. A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus. Br J Dermatol. 2009;161:1365-70.
81. Kossard S. Postmenopausal frontal fibrosing alopecia. Scarring alopecia in a pattern distribution. Arch Dermatol. 1994;130:1407.
82. Serrano S, Martín A, Sánchez J. Piccardi-Graham Little-Lasseur sindrome. Actas Dermosifiliogr. 1981;72:257-60.
83. Mehregan DA, van Hale HM, Muller SA. Lichen plano pilaris: Clinical and pathologic study of forty-five patients. J Am Acad Dermatol. 1992;27:935-42.
84. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
85. Newton RC, Hebert AA, Freese TW, Solomon AR. Scarring alopecia. Dermatol Clin. 1987;5:603-18.
86. Wiseman MC, Shapiro J. Scarring alopecia. J Cutan Med Surg. 1999;3(Suppl.3):S45-8.
87. van Beek MJ, Piette WW. Antimalarials. Dermatol Clin. 2001;19:147-60.
88. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol. 2003;21:335-76.
89. Ziegler HK, Unanue ER. Decrease in macrophage antigen catabolism caused by ammonia and chloroquine is associated with inhibition of antigen presentation to T cells. Proc Natl Acad Sci USA. 1982;79:175-8.
90. Shapiro J. Cicatricial alopecias. Dermatol Ther. 2008;21:211.
91. Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006;25:56-9.
92. Mirmirani P, Willey A, Price VH. Short course of oral cyclosporine in lichen plano pilaris. J Am Acad Dermatol. 2003;49:667-71.
93. Heymann WR. Mycophenolate mofetil. J Am Acad Dermatol. 2005;53:1045-6.
94. Tursen U, Api H, Kaya T, Ikizoglu G. Treatment of lichen plano pilaris with mycophenolate mofetil. Dermatol Online J. 2004;10:24.
95. Handler HL. Isotretinoin for oral lichen planus. J Am Acad Dermatol. 1984;10:674.
96. Sullivan JR, Kossard S. Acquired scalp alopecia. Part I: A review. Australas J Dermatol. 1998;39:207-19.
97. Helfman RJ, Brickman M, Fahey J. Isotretinoin dermatitis simulating acute pityriasis rosea. Cutis. 1984;33:297-300.
98. Berger RS, Hayes TJ, Dixon SL. Erythema dyschromicum perstans and lichen planus: Are they related? J Am Acad Dermatol. 1989;21:438-42.
99. Jiang H, Yamamoto S, Kato R. Induction of anagen in telogen mouse skin by topical application of FK506, a potent immunosuppressant. J Invest Dermatol. 1995;104:523-5.
100. Cevasco NC, Bergfeld WF, Remzi BK, de Knott HR. A case-series of 29 patients with lichen plano pilaris: The Cleveland Clinic Foundation experience on evaluation, diagnosis, and treatment. J Am Acad Dermatol. 2007;57:47-53.
101. Brocq L, Lenglet E, Ayrignac J. Recherchers sur alopecie atrophiante variante seudo-pelade. Ann Dermato Syphil. 1905;6:1-32.
102. Sperling LC, Cowper SE. The histopathology of primary cicatricial alopecia. Semin Cutan Med Surg. 2006;25:41-50.
103. Sellheyer K, Bergfeld WF. Histopathologic evaluation of alopecias. Am J Dermatopathol. 2006;28:236-59.
104. Sullivan JR, Kossard S. Acquired scalp alopecia. Part I: A review. Australas J Dermatol. 1998;39:207-19.
105. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
106. Sperling LC, Solomon AR, Whiting DA. A new look at scarring alopecia. Arch Dermatol. 2000;136:235-42.
107. Sahl WJ. Pseudopelade: An inherited alopecia. Int J Dermatol. 1996;35:715-9.
108. Collier PM, James MP. Pseudopelade of Brocq occurring in two brothers in childhood. Clin Exp Dermatol. 1994;19:61-4.
109. Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: Clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50:25-32.
110. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
111. Shapiro J. Cicatricial (scarring) alopecias. Shapiro J, editor. Hair loss: principles of diagnosis and management of alopecia. London: Martin Dunitz; 2002.p. 155-74.
112. Wiseman MC, Shapiro J. Scarring alopecia. J Cutan Med Surg. 1999;3(Suppl.3):S45-8.
113. Price VH. The medical treatment of cicatricial alopecia. Semin Cutan Med Surg. 2006;25:56-9.
114. Gruenfeld RL. Uber folliculitis decalvans. J Arch Dermatol Res. 1909;95:331-66.
115. Sperling LC, Skelton HG 3rd, Smith KJ, Sau P, Friedman K. Follicular degeneration syndrome in men. Arch Dermatol. 1994;130:763-9.
116. Olsen EA, Callender V, Sperling L, McMichael A, Anstrom KJ, Bergfeld W, et al. Central scalp alopecia photographic scale in African American women. Dermatol Ther. 2008;21:264-7.
117. LoPresti P, Papa CM, Kligman AM. Hot comb alopecia. Arch Dermatol. 1968;98:234-8.
118. Callender VD, McMichael AJ, Cohen GF. Medical and surgical therapies for alopecias in black women. Dermatol Ther. 2004;17:164-76.
119. Khumalo NP. Grooming and central centrifugal cicatricial alopecia. J Am Acad Dermatol. 2010;62:507-8.
120. Templeton SF, Solomon AR. Scarring alopecia: A classification based on microscopic criteria. J Cutan Pathol. 1994;21:97-109.
121. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
122. Sperling LC, Solomon AR, Whiting DA. A new look at scarring alopecia. Arch Dermatol. 2000;136:235-42.
123. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. 2nd edition. New York: McGraw-Hill; 2003 p. 363-98.
124. Newton RC, Hebert AA, Freese TW, Solomon AR. Scarring alopecia. Dermatol Clin. 1987;5:603-18.
125. Karpouzis A, Giatromanolaki A, Sivridis E, Kouskoukis C. Perifolliculitis capitis abscedens et suffodiens successfully controlled with topical isotretinoin. Eur J Dermatol. 2003;13:192-5.
126. Ljubojevic S, Pasic A, Lipozencic J, Skerlev M. Perifolliculitis capitis abscedens et suffodiens. J Eur Acad Dermatol Venereol. 2005;19:719-21.
127. Bolz S, Jappe U, Hartschuh W. Successful treatment of perifolliculitis capitis abscedens et suffodiens with combined isotretinoin and dapsone. J Dtsch Dermatol Ges. 2008;6:44-7.
128. Berne B, Venge P, Ohman S. Perifolliculitis capitis abscedens et suffodiens (Hoffman). Complete healing associated with oral zinc therapy. Arch Dermatol. 1985;121:1028-30.
129. Georgala S, Korfitis C, Ioannidou D, Alestas T, Kylafis G, Georgala C. Dissecting cellulitis of the scalp treated with rifampicin and isotretinoin: Case reports. Cutis. 2008;82:195-8.
130. Wu WY, Otberg N, McElwee KJ, Shapiro J. Diagnosis and management of primary cicatricial alopecia: Part II. Skinmed. 2008;7:78-83.
131. Navarini AA, Trüeb RM. 3 cases of dissecting cellulitis of the scalp treated with adalimumab: Control of inflammation within residual structural disease. Arch Dermatol. 2010;146:517-20.
132. Krasner BD, Hamzavi FH, Murakawa GJ, Hamzavi IH. Dissecting cellulitis treated with the long-pulsed Nd: YAG laser. Dermatol Surg. 2006;32:1039-44.
133. Whiting DA. Cicatricial alopecia: Clinico-pathological findings and treatment. Clin Dermatol. 2001;19:211-25.
134. Tan E, Martinka M, Ball N, Shapiro J. Primary cicatricial alopecias: Clinicopathology of 112 cases. J Am Acad Dermatol. 2004;50:25-32.
135. Chandrawansa PH, Giam YC. Folliculitis decalvans –a retrospective study in a tertiary referred centre, over five years. Singapore Med J. 2003;44:84-7.
136. Powell JJ, Dawber RP, Gatter K. Folliculitis decalvans including tufted folliculitis: Clinical, histological and therapeutic findings. Br J Dermatol. 1999;140:328-33.
137. Powell J, Dawber RP. Successful treatment regime for folliculitis decalvans despite uncertainty of all aetiological factors. Br J Dermatol. 2001;144:428-9.
138. Annessi G. Tufted folliculitis of the scalp: A distinctive clinicohistological variant of folliculitis decalvans. Br J Dermatol. 1998;138:799-805.
139. Ross EK, Tan E, Shapiro J. Update on primary cicatricial alopecias. J Am Acad Dermatol. 2005;53:1-37.
140. Sullivan JR, Kossard S. Acquired scalp alopecia. Part II: A review. Australas J Dermatol. 1999;40:61-70.
141. Abeck D, Korting HC, Braun-Falco O. Folliculitis decalvans. Longlasting response to combined therapy with fusidic acid and zinc. Acta Derm Venereol. 1992;72:143-5.
142. Kaur S, Kanwar AJ. Folliculitis decalvans: Successful treatmentwith a combination of rifampicin and topical mupirocin. J Dermatol. 2002;29:180-1.
143. Powell J, Dawber RP. Folliculitis decalvans and tufted folliculitis are specific infective diseases that may lead to scarring, but are not a subset of central centrifugal scarring alopecia. Arch Dermatol. 2001;137:373-4.
144. Brozena SJ, Cohen LE, Fenske NA. Folliculitis decalvans –response to rifampicin. Cutis. 1988;42:512-5.
145. Bergfeld WF, Elston DM. Cicatricial alopecia. In: Olsen EA editor. Disorders of hair growth: Diagnosis and treatment. Second edition. New York; McGraw-Hill, New York: 2003 P.
146. Gemmeke A, Wollina U. Folliculitis decalvans of the scalp: Response to triple therapy with isotretinoin, clindamycin, and prednisolone. Acta Dermatovenerol Alp Panonica Adriat. 2006;15:184-6.
147. Paquet P, Piérard GE. Dapsone treatment of folliculitis decalvans. Ann Dermatol Venereol. 2004;131:195-7.
148. Salinger D. Treatment of folliculitis decalvans with tyrosine. Exp Dermatol. 1999;8:363-4.
149. Walker SL, Smith HR, Lun K, Griffiths WA. Improvement of folliculitis decalvans following shaving of the scalp. Br J Dermatol. 2000;142:1245-6.
150. Parlette EC, Kroeger N, Ross EV. Nd: YAG laser treatment of recalcitrant folliculitis decalvans. Dermatol Surg. 2004;30:1152-4.
Cómo citar
1.
Jiménez SB, Uribe C, Restrepo I. Guías para el manejo de las enfermedades más frecuentes del pelo. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 18 de febrero de 2019 [citado 19 de abril de 2024];20(1):54-75. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/210
Descargas
Los datos de descargas todavía no están disponibles.
Descargas
Publicado
2019-02-18
Cómo citar
1.
Jiménez SB, Uribe C, Restrepo I. Guías para el manejo de las enfermedades más frecuentes del pelo. rev. asoc. colomb. dermatol. cir. dematol. [Internet]. 18 de febrero de 2019 [citado 19 de abril de 2024];20(1):54-75. Disponible en: https://revista.asocolderma.org.co/index.php/asocolderma/article/view/210
Número
Sección
Artículo de revisión
| Estadísticas de artículo | |
|---|---|
| Vistas de resúmenes | |
| Vistas de PDF | |
| Descargas de PDF | |
| Vistas de HTML | |
| Otras vistas | |
